Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
NCT ID: NCT00667251
Last Updated: 2025-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
652 participants
INTERVENTIONAL
2008-10-07
2022-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
NCT00021255
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
NCT02238509
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
NCT00047255
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01301729
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
NCT00841828
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Prior (neo) adjuvant HER2/neu targeted therapy (yes, no)
* Prior (neo) adjuvant taxane chemotherapy (yes, no)
* Planned taxane treatment (once weekly paclitaxel versus docetaxel once every 3 weeks)
* Liver metastasis (yes, no)
Subjects were randomized 1:1 to the following treatments to a planned sample size of approximately 600 subjects (to achieve 536 centrally confirmed HER2 positive subjects):
* Taxane based chemotherapy plus lapatinib for 24 weeks followed by single agent lapatinib
* Taxane based chemotherapy plus trastuzumab for 24 weeks followed by single agent trastuzumab
The choice of taxane (once weekly paclitaxel versus docetaxel once every 3 weeks) was at the discretion of the treating physician and was specified at the time of subject randomization.
A protocol-specified interim analysis was conducted on 27-Apr-2012, following which the participants in the Lapatinib plus taxane based chemotherapy arm could cross over to Taxane based chemotherapy plus Trastuzumab.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lapatinib
Plus taxane based chemotherapy
docetaxel
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
lapatinib ditosylate
1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
paclitaxel
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Trastuzumab
Plus taxane based chemotherapy.
trastuzumab
IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
docetaxel
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
paclitaxel
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
trastuzumab
IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
docetaxel
75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
lapatinib ditosylate
1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
paclitaxel
80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MBC (stage IV) at primary diagnosis or at relapse after curative intent therapy.
* Local or central laboratory confirmed HER2/neu overexpressing and/or amplified disease in the invasive component of the primary or metastatic lesion as defined by:
1. 3+ over expression by immunohistochemistry (IHC) (\>30% of invasive tumour cells);
2. 2+ or 3+ (in 30% or less neoplastic cells) overexpression by IHC analysis AND fluorescence or chromogenic in situ hybridization (FISH/CISH) test demonstrating HER2/neu gene amplification;
3. HER2/neu gene amplification by FISH/CISH \[\>6 HER2/neu gene copies per nucleus, or a FISH/CISH ratio (HER2 gene copies to chromosome 17 signals) of \>=2.2\]
* Subjects must have had evidence of metastatic disease, but measurable disease was not mandatory. To be considered evaluable for overall response rate (CR and PR), subjects must have had at least 1 measurable lesion as follows:
1. X-ray, physical exam \>=20 mm.
2. Conventional computed tomography (CT) scan, magnetic resonance imaging (MRI) \>=20 mm.
3. Spiral CT scan \>=10 mm.
Exclusion Criteria
* Subjects who had received prior chemotherapy, immunotherapy, biologic therapy or HER2/neu targeted therapy for recurrent or MBC.
* Subjects receiving ongoing anti-cancer treatment or other investigational anti-cancer agents for breast cancer or subjects who had used an investigational drug within 30 days or 5 half-lives (if known), whichever was longer, preceding the date of randomization.
* Subjects with: CNS metastases (including leptomeningeal involvement), serious cardiac illness, peripheral neuropathy grade 2 or greater, subjects with gastrointestinal tract disease, subjects receiving CYP3A4 inhibitors or inducers, and subjects with history of allergic or hypersensitivity reactions to any study drug or their excipients.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NCIC Clinical Trials Group
NETWORK
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Anchorage, Alaska, United States
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Hot Springs, Arkansas, United States
Novartis Investigative Site
Berkeley, California, United States
Novartis Investigative Site
Highland, California, United States
Novartis Investigative Site
Montebello, California, United States
Novartis Investigative Site
Colorado Springs, Colorado, United States
Novartis Investigative Site
Denver, Colorado, United States
Novartis Investigative Site
Greenwich, Connecticut, United States
Novartis Investigative Site
Southington, Connecticut, United States
Novartis Investigative Site
Stamford, Connecticut, United States
Novartis Investigative Site
Trumbull, Connecticut, United States
Novartis Investigative Site
Waterbury, Connecticut, United States
Novartis Investigative Site
Kissimmee, Florida, United States
Novartis Investigative Site
Loxahatchee Groves, Florida, United States
Novartis Investigative Site
New Port Richey, Florida, United States
Novartis Investigative Site
Augusta, Georgia, United States
Novartis Investigative Site
Lawrenceville, Georgia, United States
Novartis Investigative Site
Savannah, Georgia, United States
Novartis Investigative Site
Post Falls, Idaho, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Oak Lawn, Illinois, United States
Novartis Investigative Site
Evansville, Indiana, United States
Novartis Investigative Site
Goshen, Indiana, United States
Novartis Investigative Site
Munster, Indiana, United States
Novartis Investigative Site
New Albany, Indiana, United States
Novartis Investigative Site
Towson, Maryland, United States
Novartis Investigative Site
Wheaton, Maryland, United States
Novartis Investigative Site
Bozeman, Montana, United States
Novartis Investigative Site
Grand Island, Nebraska, United States
Novartis Investigative Site
Kearney, Nebraska, United States
Novartis Investigative Site
Kearney, Nebraska, United States
Novartis Investigative Site
Denville, New Jersey, United States
Novartis Investigative Site
Parsippany, New Jersey, United States
Novartis Investigative Site
Cooperstown, New York, United States
Novartis Investigative Site
Greensboro, North Carolina, United States
Novartis Investigative Site
Canton, Ohio, United States
Novartis Investigative Site
Wooster, Ohio, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States
Novartis Investigative Site
Columbia, South Carolina, United States
Novartis Investigative Site
Memphis, Tennessee, United States
Novartis Investigative Site
Chesapeake, Virginia, United States
Novartis Investigative Site
Salem, Virginia, United States
Novartis Investigative Site
Bellevue, Washington, United States
Novartis Investigative Site
Kirkland, Washington, United States
Novartis Investigative Site
Mount Vernon, Washington, United States
Novartis Investigative Site
Seattle, Washington, United States
Novartis Investigative Site
Sequim, Washington, United States
Novartis Investigative Site
Tacoma, Washington, United States
Novartis Investigative Site
Wenatchee, Washington, United States
Novartis Investigative Site
Milwaukee, Wisconsin, United States
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Cipolletti, Río Negro Province, Argentina
Novartis Investigative Site
Viedma, Río Negro Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, , Argentina
Novartis Investigative Site
Santa Fe, , Argentina
Novartis Investigative Site
Garran, Australian Capital Territory, Australia
Novartis Investigative Site
Liverpool, New South Wales, Australia
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Tweed Heads, New South Wales, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Kurralta Park, South Australia, Australia
Novartis Investigative Site
Hobart, Tasmania, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Fitzroy, Victoria, Australia
Novartis Investigative Site
Wodonga, Victoria, Australia
Novartis Investigative Site
Subiaco, Western Australia, Australia
Novartis Investigative Site
Ghent, , Belgium
Novartis Investigative Site
Jette, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Namur, , Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Kelowna, British Columbia, Canada
Novartis Investigative Site
Surrey, British Columbia, Canada
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Victoria, British Columbia, Canada
Novartis Investigative Site
Winnipeg, Manitoba, Canada
Novartis Investigative Site
Moncton, New Brunswick, Canada
Novartis Investigative Site
Saint John, New Brunswick, Canada
Novartis Investigative Site
Barrie, Ontario, Canada
Novartis Investigative Site
Greater Sudbury, Ontario, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Kingston, Ontario, Canada
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Newmarket, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Sault Ste. Marie, Ontario, Canada
Novartis Investigative Site
St. Catharines, Ontario, Canada
Novartis Investigative Site
Thunder Bay, Ontario, Canada
Novartis Investigative Site
Charlottetown, Prince Edward Island, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Regina, Saskatchewan, Canada
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Novartis Investigative Site
Angers, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Metz-Tessy, , France
Novartis Investigative Site
Nantes, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Strasbourg, , France
Novartis Investigative Site
Heidelberg, Baden-Wurttemberg, Germany
Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany
Novartis Investigative Site
Coburg, Bavaria, Germany
Novartis Investigative Site
Eggenfelden, Bavaria, Germany
Novartis Investigative Site
Fürth, Bavaria, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Rosenheim, Bavaria, Germany
Novartis Investigative Site
Weiden, Bavaria, Germany
Novartis Investigative Site
Fürstenwalde, Brandenburg, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Fulda, Hesse, Germany
Novartis Investigative Site
Lich, Hesse, Germany
Novartis Investigative Site
Goslar, Lower Saxony, Germany
Novartis Investigative Site
Hanover, Lower Saxony, Germany
Novartis Investigative Site
Leer, Lower Saxony, Germany
Novartis Investigative Site
Bielefeld, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Coesfeld, North Rhine-Westphalia, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Porta Westfalica, North Rhine-Westphalia, Germany
Novartis Investigative Site
Troisdorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Velbert, North Rhine-Westphalia, Germany
Novartis Investigative Site
Witten, North Rhine-Westphalia, Germany
Novartis Investigative Site
Koblenz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Saarbrücken, Saarland, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Brandenburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Bangalore, , India
Novartis Investigative Site
Nagpur, , India
Novartis Investigative Site
Pune, , India
Novartis Investigative Site
Beersheba, , Israel
Novartis Investigative Site
Holon, , Israel
Novartis Investigative Site
Petah Tikva, , Israel
Novartis Investigative Site
Poria – Neve Oved, , Israel
Novartis Investigative Site
Ramat Gan, , Israel
Novartis Investigative Site
Lecce, Apulia, Italy
Novartis Investigative Site
Aviano (PN), Friuli Venezia Giulia, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Sora (FR), Lazio, Italy
Novartis Investigative Site
Genoa, Liguria, Italy
Novartis Investigative Site
Sassari, Sardinia, Italy
Novartis Investigative Site
Prato (PO), Tuscany, Italy
Novartis Investigative Site
Chieti, , Italy
Novartis Investigative Site
Aichi, , Japan
Novartis Investigative Site
Chiba, , Japan
Novartis Investigative Site
Ehime, , Japan
Novartis Investigative Site
Kagoshima, , Japan
Novartis Investigative Site
Kanagawa, , Japan
Novartis Investigative Site
Osaka, , Japan
Novartis Investigative Site
Osaka, , Japan
Novartis Investigative Site
Saitama, , Japan
Novartis Investigative Site
Saitama, , Japan
Novartis Investigative Site
Shizuoka, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Cuernavaca, Morelos, Mexico
Novartis Investigative Site
Ciudad Obregón, Sonora, Mexico
Novartis Investigative Site
Mexico City, , Mexico
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Delft, , Netherlands
Novartis Investigative Site
Dordrecht, , Netherlands
Novartis Investigative Site
Maastricht, , Netherlands
Novartis Investigative Site
Gdansk, , Poland
Novartis Investigative Site
Lodz, , Poland
Novartis Investigative Site
Olsztyn, , Poland
Novartis Investigative Site
Olsztyn, , Poland
Novartis Investigative Site
Płock, , Poland
Novartis Investigative Site
Rzeszów, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Arkhangelsk, , Russia
Novartis Investigative Site
Ivanovo, , Russia
Novartis Investigative Site
Kazan', , Russia
Novartis Investigative Site
Kirov, , Russia
Novartis Investigative Site
Lipetsk, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Ryazan, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Stavropol, , Russia
Novartis Investigative Site
Ufa, , Russia
Novartis Investigative Site
Gyeonggi-do, , South Korea
Novartis Investigative Site
Gyeonggi-do, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Songpa-gu, Seoul, , South Korea
Novartis Investigative Site
A Coruña, , Spain
Novartis Investigative Site
Alcorcón, , Spain
Novartis Investigative Site
Alicante, , Spain
Novartis Investigative Site
Badalona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Elche, , Spain
Novartis Investigative Site
Girona, , Spain
Novartis Investigative Site
Jaén, , Spain
Novartis Investigative Site
Lugo, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Majadahonda (Madrid), , Spain
Novartis Investigative Site
Pozuelo de Alarcon (Madrid), , Spain
Novartis Investigative Site
Seville, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Changhua, , Taiwan
Novartis Investigative Site
Taichung, , Taiwan
Novartis Investigative Site
Tainan County, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Chiang Mai, , Thailand
Novartis Investigative Site
Dnipro, , Ukraine
Novartis Investigative Site
Dnipropetrovsk, , Ukraine
Novartis Investigative Site
Lviv, , Ukraine
Novartis Investigative Site
Sumy, , Ukraine
Novartis Investigative Site
Bournemouth, , United Kingdom
Novartis Investigative Site
Brighton, , United Kingdom
Novartis Investigative Site
Chelmsford, , United Kingdom
Novartis Investigative Site
Cheltenham, , United Kingdom
Novartis Investigative Site
Colchester, , United Kingdom
Novartis Investigative Site
Cottingham, Hull, , United Kingdom
Novartis Investigative Site
Derby, , United Kingdom
Novartis Investigative Site
Edmonton, , United Kingdom
Novartis Investigative Site
Guildford, , United Kingdom
Novartis Investigative Site
Harrogate, , United Kingdom
Novartis Investigative Site
Huddersfield, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Newcastle upon Tyne, , United Kingdom
Novartis Investigative Site
Norwich, , United Kingdom
Novartis Investigative Site
Nottingham, , United Kingdom
Novartis Investigative Site
Oxford, , United Kingdom
Novartis Investigative Site
Poole, Dorset, , United Kingdom
Novartis Investigative Site
Sheffield, , United Kingdom
Novartis Investigative Site
Shrewsbury, , United Kingdom
Novartis Investigative Site
Sutton, , United Kingdom
Novartis Investigative Site
Whitchurch, Cardiff, , United Kingdom
Novartis Investigative Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol. 2015 May 10;33(14):1574-83. doi: 10.1200/JCO.2014.56.9590. Epub 2015 Mar 16.
Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Res Treat. 2017 Aug;164(3):571-580. doi: 10.1007/s10549-017-4273-x. Epub 2017 May 8.
Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Nov 9;3(11):e172085. doi: 10.1001/jamaoncol.2017.2085. Epub 2017 Nov 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLAP016A2303
Identifier Type: OTHER
Identifier Source: secondary_id
CAN-NCIC-MA31
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2007-004568-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CDR0000594764
Identifier Type: OTHER
Identifier Source: secondary_id
EGF108919
Identifier Type: OTHER
Identifier Source: secondary_id
108919
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.